A risk reduction of 34% in major cardiovascular events compared with placebo was observed, although this difference did not reach statistical significance possibly due to a lower than expected event rate.
← all excerpts
Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout.
1
—
—